Teleflex awarded Central Venous Access, Arterial Access agreements with Premier
April 29 2020 - 5:15PM
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies for critical care and surgery, has been
awarded group purchasing agreements for Central Venous Access and
Arterial Access with Premier, effective July 1.
Premier has awarded Teleflex a multi-source Central Venous
Access Product and sole source Arterial Catheter agreement for
National members. A sole-source Central Venous Access Product
agreement was awarded for Ascend members.
Premier is a leading healthcare improvement company, uniting an
alliance of approximately 4,000 U.S. hospitals and 175,000 other
providers to transform healthcare. With integrated data and
analytics, collaboratives, supply chain solutions, and advisory and
other services, Premier enables better care and outcomes at a lower
cost.
These new agreements allow Premier members, at their discretion,
to take advantage of special pricing and terms pre-negotiated by
Premier for CVC and Arterial Vascular Access Products.
“Teleflex works to develop Arrow® Brand vascular access products
that are designed to equally benefit clinicians and patients, help
protect against vascular access related complications like
infection, thrombosis, and tip malposition, and help clinicians
follow independent third-party vascular access guidelines” said
Jake Newman, President and General Manager, Teleflex Vascular. “As
the market leader in CVCs and Arterial devices1-2, we are pleased
to offer Premier members one of the broadest portfolios of central
access and arterial access products available.”
Teleflex, through its Arrow® Brand of CVC products, has been
innovating for more than four decades to help healthcare providers
optimize patient outcomes, minimize the risk of central
line-associated infections (CLABSI), and efficiently streamline
insertion procedures.
Antimicrobial Arrowg+ard Blue Plus® CVCs are the only
full-spectrum antimicrobial CVCs that protect against both
gram-positive and gram-negative bacteria, fungi, and demonstrate a
67-100% reduction in CLABSI3-6.
Combined with antimicrobial Arrowg+ard Blue Plus® CVCs, Arrow®
ErgoPack® Systems help make it easy to:
- Standardize vascular access across a system
- Maintain a high standard of patient care
- Control costs and risks from infections
Arrow® ErgoPack® Systems help clinicians comply with third-party
guideline recommendations7-10, including:
- CDC Category 1A &1B Recommendations
- SHEA Guidelines
- INS Standards of Practice
- OSHA Bloodborne Pathogens Standard
The Arrow® Brand of arterial access products contains a
comprehensive portfolio of catheters designed to accommodate a
variety of insertion location and placement techniques.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular access, interventional
cardiology and radiology, anesthesia, emergency medicine, surgical,
urology and respiratory care. Teleflex employees worldwide are
united in the understanding that what we do every day makes a
difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch®, UroLift®, and Weck® – trusted brands united by a
common sense of purpose.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Plus,
Deknatel, ErgoPack, Hudson RCI, LMA, Pilling, Rusch, Urolift, and
Weck are trademarks or registered trademarks of Teleflex
Incorporated or its affiliates, in the U.S. and/or other countries.
© 2020 Teleflex Incorporated. All rights reserved. MC-006396 Rev
0
References
- IMS Data. Data based on 2019 Q4 Total Acute CVC market unit
share for Teleflex. 2019.
- IMS Data. Data based on 2019 Q4 Total Arterial market unit
share for Teleflex. 2019.
- Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a
Second-Generation Venous Catheter Impregnated with Chlorhexidine
and Silver Sulfadiazine of Central Catheter-Related Infections. Ann
Intern Medicine. 2005; 143: 570-80. Sponsored by Arrow
(Teleflex).
- Lorente L, Lecuona M, Jimenez A, et al. Chlorhexidine-silver
sulfadiazine-impregnated venous catheters save costs. American
Journal of Infection Control. 2014; 42: 321-4.
- Lorente L, Lecuona M, Jimenez A, et al. Cost/benefit analysis
of chlorhexidine-silver sulfadiazine-impregnated venous catheters
for femoral access. American Journal of Infection Control. 2014;
42: 1130-2.
- Lorente, L, et al. Chlorhexidine-silver
sulfadiazine-impregnated venous catheters are efficient even at
subclavian sites without tracheostomy. American journal of
infection control. 2016; 44(12): 1526-29. Zimlichman, E, et
al.
- O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the
Prevention of Intravascular Catheter-Related Infections, 2011
(Revised 2017). 2. Atlanta, GA: Centers for Disease Control and
Prevention; 2017.
- Marschall J, Mermel LA, Fakih M, et al. Strategies to Prevent
Central Line–Associated Bloodstream Infections in Acute Care
Hospitals: 2014 Update. Infection Control and Hospital
Epidemiology. 2014 July; 35(7): 753-71.
- Gorski L, Hadaway L, Hagle ME, McGoldrick M, et al. Infusion
Therapy Standards of Practice. Journal of Infusion Nursing. 2016;
Jan 39(1S).
- Occupational Safety & Health Administration Regulations
(Standards – 29 CFR). Part 1910.1030: Bloodborne pathogens.
Occupational Safety & Health Administration Web site.
https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030.
Accessed on February 12, 2020.
Source: Teleflex IncorporatedJake
ElguiczeTreasurer and Vice President, Investor
Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2024 to May 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From May 2023 to May 2024